Gilead Sciences GILD Biktarvy — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's biktarvy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's biktarvy — total revenues?
- Gilead Sciences (GILD) reported biktarvy — total revenues of $3.36B in Q1 2026.
- How has Gilead Sciences's biktarvy — total revenues changed year-over-year?
- Gilead Sciences's biktarvy — total revenues increased by 6.7% year-over-year, from $3.15B to $3.36B.
- What is the long-term trend for Gilead Sciences's biktarvy — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's biktarvy — total revenues has grown at a 13.5% compound annual growth rate (CAGR), from $8.62B to $14.33B.
- What does biktarvy — total revenues mean?
- The total sales revenue generated by the company's leading HIV medication.
- How do you interpret biktarvy — total revenues?
- An increase indicates strong market penetration, successful patient retention, or favorable pricing dynamics for the product, while a decrease may signal increased competition, patent expiration risks, or shifts in treatment guidelines.
- How does biktarvy — total revenues compare across companies?
- Comparable to revenue metrics for specific blockbuster pharmaceutical products or key therapeutic franchises at peer biopharmaceutical companies.